Hugo Larochelle appointed Scientific Director of Mila
An adjunct professor at the Université de Montréal and former head of Google's AI lab in Montréal, Hugo Larochelle is a pioneer in deep learning and one of Canada’s most respected researchers.
Mila’s AI for Climate Studio aims to bridge the gap between technology and impact to unlock the potential of AI in tackling the climate crisis rapidly and on a massive scale.
The program recently published its first policy brief, titled "Policy Considerations at the Intersection of Quantum Technologies and Artificial Intelligence," authored by Padmapriya Mohan.
We use cookies to analyze the browsing and usage of our website and to personalize your experience. You can disable these technologies at any time, but this may limit certain functionalities of the site. Read our Privacy Policy for more information.
Setting cookies
You can enable and disable the types of cookies you wish to accept. However certain choices you make could affect the services offered on our sites (e.g. suggestions, personalised ads, etc.).
Essential cookies
These cookies are necessary for the operation of the site and cannot be deactivated. (Still active)
Analytics cookies
Do you accept the use of cookies to measure the audience of our sites?
Multimedia Player
Do you accept the use of cookies to display and allow you to watch the video content hosted by our partners (YouTube, etc.)?
Publications
AURA: A Multi-Modal Medical Agent for Understanding, Reasoning&Annotation
Recent advancements in Large Language Models (LLMs) have catalyzed a paradigm shift from static prediction systems to agentic AI agents capa… (see more)ble of reasoning, interacting with tools, and adapting to complex tasks. While LLM-based agentic systems have shown promise across many domains, their application to medical imaging remains in its infancy. In this work, we introduce AURA, the first visual linguistic explainability agent designed specifically for comprehensive analysis, explanation, and evaluation of medical images. By enabling dynamic interactions, contextual explanations, and hypothesis testing, AURA represents a significant advancement toward more transparent, adaptable, and clinically aligned AI systems. We highlight the promise of agentic AI in transforming medical image analysis from static predictions to interactive decision support. Leveraging Qwen-32B, an LLM-based architecture, AURA integrates a modular toolbox comprising: (i) a segmentation suite with phase grounding, pathology segmentation, and anatomy segmentation to localize clinically meaningful regions; (ii) a counterfactual image-generation module that supports reasoning through image-level explanations; and (iii) a set of evaluation tools including pixel-wise difference-map analysis, classification, and advanced state-of-the-art components to assess diagnostic relevance and visual interpretability.
Changepoint detection is a technique used to identify significant shifts in sequences and is widely used in fields such as finance, genomics… (see more), and medicine. To identify the changepoints, dynamic programming (DP) algorithms, particularly Optimal Partitioning (OP) family, are widely used. To control the changepoints count, these algorithms use a fixed penalty to penalize the changepoints presence. To predict the optimal value of that penalty, existing methods used simple models such as linear or tree-based, which may limit predictive performance. To address this issue, this study proposes using a multilayer perceptron (MLP) with a ReLU activation function to predict the penalty. The proposed model generates continuous predictions -- as opposed to the stepwise ones in tree-based models -- and handles non-linearity better than linear models. Experiments on large benchmark genomic datasets demonstrate that the proposed model improves accuracy and F1 score compared to existing models.
Obeticholic acid (OCA) is the second line therapy for primary biliary cholangitis. While efficient in promoting BA detoxification and limiti… (see more)ng liver fibrosis, its clinical use is restricted by severe dose-dependent side effects. We tested the hypothesis that adding n-3 polyunsaturated fatty acids, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids to OCA may improve the therapeutic effect of the low drug dosage. Several liver cell lines were exposed to vehicle, low or high OCA dose (1-20μM) in the presence or absence of EPA/DHA for 24H. To induce ER stress, apoptosis, and fibrosis, HepG2 cells were exposed to a 400μM BA mixture or to 2ng/mL TGF-β. For inflammation analyses, THP-1 cells were activated with 100ng/mL LPS. The impact OCA+EPA/DHA was assessed using transcriptomic (qRT-PCR), proteomic (ELISA, caspase-3), and metabolomic (LC-MS/MS) approaches. The addition of EPA/DHA reinforced the ability of low OCA dose to down-regulate the expression of genes involved in BA synthesis (CYP7A1, CYP8B1) and uptake (NTCP) and to up-regulate MRP2 & 3 genes expression. EPA/DHA also enhanced the anti-inflammatory response of the drug by reducing the expression of the LPS-induced cytokines: TNFα, IL-6, IL-1β and MCP-1 in THP-1 macrophages. OCA+EPA/DHA decreased the expression of BIP, CHOP and COL1A1 genes and the caspase-3 activity. EPA+DHA potentiate the response to low OCA doses on BA toxicity, and provide additional benefits on ER stress, apoptosis, inflammation and fibrosis. These observations support the idea that adding n-3 polyunsaturated fatty acids to the drug may reduce the risk of dose-related side effects in patients treated with OCA.
Choice of immunoassay influences population seroprevalence estimates. Post-hoc adjustments for assay performance could improve comparability… (see more) of estimates across studies and enable pooled analyses. We assessed post-hoc adjustment methods using data from 2021–2023 SARS-CoV-2 serosurveillance studies in Alberta, Canada: one that tested 124,008 blood donations using Roche immunoassays (SARS-CoV-2 nucleocapsid total antibody and anti-SARS-CoV-2 S) and another that tested 214,780 patient samples using Abbott immunoassays (SARS-CoV-2 IgG and anti-SARS-CoV-2 S). Comparing datasets, seropositivity for antibodies against nucleocapsid (anti-N) diverged after May 2022 due to differential loss of sensitivity as a function of time since infection. The commonly used Rogen-Gladen adjustment did not reduce this divergence. Regression-based adjustments using the assays’ semi-quantitative results produced more similar estimates of anti-N seroprevalence and rolling incidence proportion (proportion of individuals infected in recent months). Seropositivity for antibodies targeting SARS-CoV-2 spike protein was similar without adjustment, and concordance was not improved when applying an alternative, functional threshold. These findings suggest that assay performance substantially impacted population inferences from SARS-CoV-2 serosurveillance studies in the Omicron period. Unlike methods that ignore time-varying assay sensitivity, regression-based methods using the semi-quantitative assay resulted in increased concordance in estimated anti-N seropositivity and rolling incidence between cohorts using different assays.
Corrigendum to "Child- and Proxy-reported Differences in Patient-reported Outcome and Experience Measures in Pediatric Surgery: Systematic Review and Meta-analysis" [Journal of Pediatric Surgery 60 (2025) 162172].
Corrigendum to "Child- and Proxy-reported Differences in Patient-reported Outcome and Experience Measures in Pediatric Surgery: Systematic Review and Meta-analysis" [Journal of Pediatric Surgery 60 (2025) 162172].
Corrigendum to "Virtual Reality for Pediatric Trauma Education - A Preliminary Face and Content Validation Study" [Journal of Pediatric Surgery 60 (2025) 161951].
Corrigendum to "Virtual Reality for Pediatric Trauma Education - A Preliminary Face and Content Validation Study" [Journal of Pediatric Surgery 60 (2025) 161951].
Employing Machine Learning to Predict Medical Trainees’ Psychophysiological Responses and Self- and Socially- Shared Regulated Learning Strategies While Completing Medical Simulations